Vimovo. Vimovo has been approved by FDA. Vimovo information
Recently Food and Medicines Administration USA approved Vimovo containing naproxen and esomeprasol for treating patients with arthritis with increased risk if NSAID-associated gastric ulcers. Vimovo is used to relieve symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, as well as to reduce the risk of stomach ulcers in patients with high risk of developing NSAID-associated ulcers. The medication contains two active ingredients – naproxen. Naproxen is a painkiller that belongs to a group of medicines called NSAID’s. The second component of Vimovo is esomeprasole that is immediate release proton pump inhibitor. Esomeprasole works by inhibiting the production of gastric acid for the stomach. FDA decision is based on the results of the clinical trials showed a significant reduction in the incidence of gastric ulcers compared with naproxen in monotherapy (4% vs. 23%).
Feb 22, 2014